Metabolic monitoring training program implementation in the community setting was associated with improved monitoring in second-generation antipsychotic-treated children

Canadian Journal of Psychiatry

Volumn 57, Issue 5, 2012, Pages 292-299

  Ronsley, Rebecca ^a   Rayter, Mark ^b   Smith, Derryck ^b,c   Davidson, Jana ^c,d   Panagiotopoulos, Constadina ^c,d,e  

^a UNIVERSITY OF TORONTO   (Canada)

^b VANCOUVER COASTAL HEALTH   (Canada)

^c UNIVERSITY OF BRITISH COLUMBIA   (Canada)

^d BC CHILDREN S HOSPITAL   (Canada)

^e UNIVERSITY OF BRITISH COLUMBIA   (Canada)

Author keywords

Children; Community; Metabolic monitoring; Second generation antipsychotic

Indexed keywords

ANTIDEPRESSANT AGENT; ANXIOLYTIC AGENT; ATOMOXETINE; FIRST GENERATION ANTIPSYCHOTIC AGENT; NEUROLEPTIC AGENT; PSYCHOSTIMULANT AGENT; SECOND GENERATION ANTIPSYCHOTIC AGENT; UNCLASSIFIED DRUG;

ADOLESCENT; ADULT; ANTHROPOMETRY; ARTICLE; CHILD; CONTROLLED STUDY; ELECTRONIC MEDICAL RECORD; HEALTH PROGRAM; HUMAN; MAJOR CLINICAL STUDY; MEDICAL RECORD; METABOLIC MONITORING TRAINING PROGRAM; MOOD; PRESCHOOL CHILD; SCHOOL CHILD;

EID: 84869232530     PISSN: 07067437     EISSN: 14970015     Source Type: Journal    
DOI: 10.1177/070674371205700504     Document Type: Article

References (28)

1. Olfson M, Crystal S, Huang C, et al. Trends in antipsychotic drug use by very young, privately insured children. J Am Acad Child Adolesc Psychiatry. 2010;49(1):13-23.
2. Domino ME, Swartz MS. Who are the new users of antipsychotic medications? Psychiatr Serv. 2008;59(5):507-514.
3. Panagiotopoulos C, Ronsley R, Elbe D, et al. First do no harm: promoting an evidence-based approach to atypical antipsychotic use in children and adolescents. J Can Acad Child Adolesc Psychiatry. 2010;19(2):124-137.
4. Panagiotopoulos C, Ronsley R, Davidson J. Increased prevalence of obesity and glucose intolerance in youth treated with second-generation antipsychotic medications. Can J Psychiatry. 2009;54(11):743-749.
5. Correll CU, Manu P, Olshanskiy V, et al. Cardiometabolic risk of second-generation antipsychotic medications during first-time use in children and adolescents. JAMA. 2009;302(16):1765-1773.
6. Burns TL, Letuchy EM, Paulos R, et al. Childhood predictors of the metabolic syndrome in middle-aged adults: the Muscatine study. J Pediatr. 2009;155(3):S5.e17-e26.
7. Hacihamdioǧlu B, Okutan V, Yozgat Y, et al. Abdominal obesity is an independent risk factor for increased carotid intima-media thickness in obese children. Turk J Pediatr. 2011;53(1):48-54.
8. Iwashima S, Nakagawa Y, Ishikawa T, et al. Abdominal obesity is associated with cardiovascular risk in Japanese children and adolescents. J Pediatr Endocrinol Metab. 2011;24(1-2):51-54.
9. Morrato EH, Newcomer JW, Kamat S, et al. Metabolic screening after the American Diabetes Association's consensus statement on antipsychotic drugs and diabetes. Diabetes Care. 2009;32(6):1037-1042.
10. Khan AY, Shaikh MR, Ablah E. To examine the extent of compliance to the proposed monitoring protocol among practicing psychiatrists for second generation antipsychotics. J Pak Med Assoc. 2010;60(6):446-450.
11. Morrato EH, Druss B, Hartung DM, et al. Metabolic testing rates in 3 state Medicaid programs after FDA warnings and ADA/APA recommendations for second-generation antipsychotic drugs. Arch Gen Psychiatry. 2010;67(1):17-24.
12. Reeves R, Kaldany H, Lieberman J, et al. Creation of a metabolic monitoring program for second-generation (atypical) antipsychotics. J Correct Health Care. 2009;15(4):292-301.
13. Haupt DW, Rosenblatt LC, Kim E, et al. Prevalence and predictors of lipid and glucose monitoring in commercially insured patients treated with second-generation antipsychotic agents. Am J Psychiatry. 2009;166(3):345-353.
14. Morrato EH, Newcomer JW, Allen RR, et al. Prevalence of baseline serum glucose and lipid testing in users of second-generation antipsychotic drugs: a retrospective, population-based study of Medicaid claims data. J Clin Psychiatry. 2008;69(2):316-322. (Pubitemid 351469276)
15. Weissman EM, Zhu CW, Schooler NR, et al. Lipid monitoring in patients with schizophrenia prescribed second-generation antipsychotics. J Clin Psychiatry. 2006;67(9):1323-1326. (Pubitemid 44583378)
16. Morrato EH, Nicol GE, Maahs D, et al. Metabolic screening in children receiving antipsychotic drug treatment. Arch Pediatr Adolesc Med. 2010;164(4):344-351.
17. American Diabetes Association, American Psychiatric Association, American Association of Clinical Endocrinologists, et al. Consensus development conference on antipsychotic drugs and obesity and diabetes. Diabetes Care. 2004;27(2):596-601.
18. Panagiotopoulos C, Ronsley R, Kuzeljevic B, et al. Waist circumference is a sensitive screening tool for assessment of metabolic syndrome risk in children treated with second-generation antipsychotics. Can J Psychiatry. 2012;57(1):34-44.
19. Pringsheim T, Panagiotopoulos C, Davidson J, et al. Evidence-based recommendations for monitoring safety of second generation antipsychotics in children and youth. J Can Acad Child Adolesc Psychiatry. 2011;20(3):218-233.
20. Panagiotopoulos C, Davidson J. Metabolic Monitoring, Screening and Assessment Tool [Internet]. Vancouver (BC): Kelty Mental Health Resource Centre; 2011 Nov 21 [cited 2012 Jan 18]. Available from: http://keltymentalhealth.ca/ partner/provincial-mental-health-metabolic-program.
21. Ronsley R, Raghuram K, Davidson J, et al. Barriers and facilitators to implementation of a metabolic monitoring protocol in hospital and community settings for second-generation antipsychotic-treated youth. J Can Acad Child Adolesc Psychiatry. 2011;20(2):134-141.
22. Panagiotopoulos C, Davidson J, Raghuram K. A physician handbook for metabolic monitoring for youth with mental illness treated with second-generation antipsychotics [Internet]. Vancouver (BC): BC Children's Hospital; 2010 Jul 21 [cited 2012 Jan 18]. Available from: http://bit.ly/ physicianhandbookformmt. Jointly published by BC Mental Health and Addiction Services.
23. Cook S, Auinger P, Li C, et al. Metabolic syndrome rates in United States adolescents, from the National Health and Nutrition Examination Survey, 1999-2002. J Pediatr. 2008;152(2):165-170.
24. Cruz ML, Goran MI. The metabolic syndrome in children and adolescents. Curr Diab Rep. 2004;4(1):53-62. (Pubitemid 39359511)
25. Shaibi GQ, Goran MI. Examining metabolic syndrome definitions in overweight Hispanic youth: a focus on insulin resistance. J Pediatr. 2008;152(2):171-176.
26. McEvoy JP, Meyer JM, Goff DC, et al. Prevalence of the metabolic syndrome in patients with schizophrenia: baseline results from the Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE) schizophrenia trial and comparison with national estimates from NHANES III. Schizophr Res. 2005;80(1):19-32. (Pubitemid 41587460)
27. Panagiotopoulos C, Louie DC, Warburton WP, et al. Trends in antipsychotic prescriptions to children and adolescents in British Columbia, Canada: 1996-2010. New Research Poster Presentation at AACAP+CACAP Joint Annual Meeting. October 18-23, 2011; Scientific Proceedings (Volume XXXVIII):268.
28. Walter G, DeLaroche A, Soh N, et al. Side effects of second-generation antipsychotics: the experiences, views and monitoring practices of Australian child psychiatrists. Australas Psychiatry. 2008;16(4):253-262.